Ribociclib Maintains Quality of Life While Extending Survival

Addition of CDK4/6 inhibitor delays health deterioration (HR 0.81) alongside proven PFS benefit (HR 0.59)

Design · Phase III Randomized Clinical Trial (MONALEESA-3) N · 726 Population · Postmenopausal HR+/HER2- Advanced Breast Cancer (1st or 2nd line) Duration · Median follow-up 20.4 months Arms · Ribociclib + Fulvestrant vs. Placebo + Fulvestrant Double-blind Placebo-controlled 2:1 Randomization

Key Performance Indicators

PRIMARY

Global Health TTD HR

0.81

95% CI: 0.62–1.1

19% risk reduction (trend)

Pain Severity TTD HR

0.77

95% CI: 0.57–1.05

Delayed pain progression

PFS Benefit (Context)

0.593

p < 0.001

Significant survival gain

Emotional Function HR

0.76

95% CI: 0.57–1.01

Better emotional stability

1

Risk of Deterioration Across QoL Domains (Hazard Ratios)

Hazard Ratios for Time to Definitive Deterioration (TTD) ≥10%. Values < 1.0 favor Ribociclib. While confidence intervals cross 1.0 (statistically non-significant), the consistent leftward shift indicates a trend of preserved quality of life despite added therapy.

2

Pain Score Trajectory Over Time (EORTC QLQ-C30)

Mean pain scores decreased (improved) early in both arms and were maintained. Lower scores indicate less pain. Ribociclib did not induce additional pain burden compared to placebo.

3

Median Time to Deterioration (Global Health) vs. PFS

Comparing the median months until 10% QoL deterioration vs. Progression-Free Survival. Ribociclib extends PFS significantly (20.5 vs 12.8) while maintaining a slightly longer time to QoL deterioration (35.9 vs 33.1).

4

Baseline Symptom Burden (Mean Scores)

Comparison of baseline symptom scores. Higher scores indicate worse symptoms. The groups were well-balanced at baseline, ensuring validity of longitudinal comparisons.

Editorial Conclusion

“Ribociclib plus fulvestrant significantly prolongs progression-free survival without compromising quality of life compared to fulvestrant monotherapy.”

Time to 10% deterioration in Global Health Status trended in favor of Ribociclib (HR 0.81).

Pain scores improved early in treatment and were maintained in both arms.

Functional scales (Physical, Emotional) showed trends toward delayed deterioration with Ribociclib.

Clinical Implication

Clinicians can prescribe this combination for survival benefits with confidence that it does not impose a detrimental QoL burden on patients.

Reference Data & Sources

Complete Data Table

Metric	Group	Value	Unit	Source
Global Health Status TTD HR	Ribociclib vs Placebo	0.81 (0.62–1.1)	HR	Abstract
Physical Functioning TTD HR	Ribociclib vs Placebo	0.82 (0.61–1.10)	HR	Results 3.3
Emotional Functioning TTD HR	Ribociclib vs Placebo	0.76 (0.57–1.01)	HR	Results 3.3
Pain Severity Index TTD HR	Ribociclib vs Placebo	0.77 (0.57–1.05)	HR	Results 3.4
Median TTD Global Health	Ribociclib	35.9	months	Fig 2a Caption/Text
Median TTD Global Health	Placebo	33.1	months	Fig 2a Caption/Text

Abbreviations

HR = Hazard Ratio · CI = Confidence Interval · TTD = Time to Definitive Deterioration · PFS = Progression-Free Survival · QoL = Quality of Life · BPI-SF = Brief Pain Inventory-Short Form

Source

Fasching et al. The Breast 54 (2020) 148-154
DOI: 10.1016/j.breast.2020.09.008

Limitations

No post-progression PRO assessments were performed. Differences in HRQOL deterioration were not statistically significant (CIs crossed 1). PROs were a secondary objective.